Literature DB >> 2162384

Plasma exchange: a treatment for neuropathy associated with IgG-kappa gammopathy.

S M Fineman1, R R McKendall.   

Abstract

A patient with a peripheral neuropathy associated with an IgG-kappa gammopathy is reported who was treated with plasma exchange as the only therapeutic modality and showed dramatic clinical improvement, which fluctuated based on the frequency of plasma exchange. Therapeutic plasma exchange is recommended as one form of possible treatment for neuropathies resulting from IgG gammopathies. The literature is reviewed.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2162384     DOI： 10.1007/BF00314667

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


  9 in total

1.  Prevalence of monoclonal protein in peripheral neuropathy.

Authors:  J J Kelly; R A Kyle; P C O'Brien; P J Dyck
Journal:  Neurology       Date:  1981-11       Impact factor: 9.910

2.  Peripheral neuropathy associated with plasma cell dyscrasia: a clinical and electrophysiological follow-up study.

Authors:  T Smith; W Sherman; M R Olarte; R E Lovelace
Journal:  Acta Neurol Scand       Date:  1987-04       Impact factor: 3.209

3.  Peripheral neuropathy and monoclonal IgM with antibody activity against peripheral nerve myelin; effect of plasma exchange.

Authors:  J Ernerudh; E Brodtkorb; T Olsson; C A Vedeler; H Nyland; G Berlin
Journal:  J Neuroimmunol       Date:  1986-05       Impact factor: 3.478

4.  Monoclonal gammopathy and neuropathy: myelin-associated glycoprotein reactivity and clinical characteristics.

Authors:  D A Hafler; D Johnson; J J Kelly; H Panitch; R Kyle; H L Weiner
Journal:  Neurology       Date:  1986-01       Impact factor: 9.910

5.  Peripheral neuropathy associated with monoclonal gammopathy. Studies of intraneural injections of monoclonal immunoglobulin sera.

Authors:  E P Bosch; L E Ansbacher; J A Goeken; P A Cancilla
Journal:  J Neuropathol Exp Neurol       Date:  1982-07       Impact factor: 3.685

6.  Treatment of patients with neuropathy and anti-MAG IgM M-proteins.

Authors:  E Nobile-Orazio; L Baldini; S Barbieri; P Marmiroli; G Spagnol; E Francomano; G Scarlato
Journal:  Ann Neurol       Date:  1988-07       Impact factor: 10.422

7.  Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia.

Authors:  D C Haas; A H Tatum
Journal:  Ann Neurol       Date:  1988-04       Impact factor: 10.422

8.  Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia.

Authors:  W H Sherman; M R Olarte; G McKiernan; K Sweeney; N Latov; A P Hays
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-08       Impact factor: 10.154

9.  Polyneuropathy with monoclonal gammopathy: studies of 11 patients.

Authors:  M C Dalakas; W K Engel
Journal:  Ann Neurol       Date:  1981-07       Impact factor: 10.422
  9 in total
  3 in total

Review 1.  Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

Authors:  Hafsa M Chaudhry; Michelle L Mauermann; S Vincent Rajkumar
Journal:  Mayo Clin Proc       Date:  2017-05       Impact factor: 7.616

Review 2.  Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy.

Authors:  J M Leger; A B Younes-Chennoufi; B Chassande; G Davila; P Bouche; N Baumann; P Brunet
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

3.  Immunotactoid-like endoneurial deposits in a patient with monoclonal gammopathy of undetermined significance and neuropathy.

Authors:  D F Moorhouse; R I Fox; H C Powell
Journal:  Acta Neuropathol       Date:  1992       Impact factor: 17.088
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.